Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers

Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancers in a Multiethnic Malaysian Patient Population

“…Significantly higher EGFR mutation rates have been found among female (45-46%), never-smoker (48.6-64.2%) and adenocarcinoma patients (38.1-55.0%) in both East Asian (Huang et al, 2004;2011) and Western (Pallis et al, 2007;Rosell et al, 2009;Sequist et al, 2011) study populations. East Asian studies with a high proportion of never smokers (61.5-100%) and female patients (49.1-78.7%) reported high mutation rates of 51.3-75.3% (Sun et al, 2010;Li et al, 2011) compared to mutation rates of 29-38.6% in other East Asian studies (Huang et al, 2004;2011) with lower proportion of never smokers (36.4-59.8%) and female patients (33.1-44.6%).…”

Establishment and characterization of primary lung cancer cell lines from Chinese population

“…Studies demonstrate that ethnic differences in genetic background are important in defining cancer biology as well as in drug toxicity [14][15][16][17][18][19][20][21] . For example, the epidermal growth factor receptor (EGFR) kinase domain mutations occur in approximately 10% of NSCLC patients in the Caucasian popula tion [22] , but occur in 30%-50% of NSCLC patients from East Asian populations [15,17,18,21,23] .…”

“…For example, the epidermal growth factor receptor (EGFR) kinase domain mutations occur in approximately 10% of NSCLC patients in the Caucasian popula tion [22] , but occur in 30%-50% of NSCLC patients from East Asian populations [15,17,18,21,23] . Ethnic differences in the expression of allelic variants may produce altered pharmacokinetics and Establishment and characterization of primary lung cancer cell lines from Chinese population www.nature.com/aps Zheng C et al Acta Pharmacologica Sinica npg result in differential toxicity for the same anticancer treatments [19,20] .…”

Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.

“…Based on previous studies of non-small cell lung cancer, EGFR mutations occurred more common in non-smoking patients. [25][26][27][28] EGFR gene mutation status has not been prospectively studied in esophageal cancer, although it has been shown to significantly correlate with the response of lung cancer patients to EGFR-TKI therapy. [29,30] In our current study, despite the small number of patients limiting the statistical power to draw a definite conclusion, it is intriguing that an EGFR mutation was associated with a better outcome tendency in gefitinibtreated patients (OS, 17 vs. 10 months in ARMS-positive and -negative patients, respectively).…”